Teva Recalls All Amlodipine/Valsartan Combination Products in US Teva Recalls All Amlodipine/Valsartan Combination Products in US
In the ongoing saga of tainted sartans, Teva recalls all amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide combination products because of contamination with NDEA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Teva to recall certain blood pressure medicine in U.S
Teva Pharmaceutical Industries Ltd is recalling certain combinations of blood pressure drug valsartan in the United States following the detection of a probable cancer-causing impurity, the latest global recall of the medicine. (Source: Reuters: Health)
Source: Reuters: Health - November 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry
Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India.
The impurity found in Mylan ’s valsartan API is known as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen. This chemical is typically found in very small amounts in certain foods, drinking water, air pollution, and c...
Source: Food and Drug Administration - November 27, 2018 Category: Food Science Source Type: news
Mylan Recalls 15 Lots of Valsartan Products in US Mylan Recalls 15 Lots of Valsartan Products in US
The Mylan recall of valsartan tablets, amlodipine/valsartan tablets, and valsartan/hydrochlorothiazide tablets marks the latest recall of sartans contaminated with probable carcinogens.News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 21, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient
Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength. These products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in...
Source: Food and Drug Administration - November 21, 2018 Category: Food Science Source Type: news
Mylan recalls batches of blood pressure medicine in U.S.
Mylan NV said on Tuesday it would recall certain batches of blood pressure medicine valsartan in the United States after they were found to contain a probable cancer-causing impurity, the latest recall amid heightened safety concerns globally. (Source: Reuters: Health)
Source: Reuters: Health - November 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Mylan recalls batches of blood pressure medicine in U.S
Drugmaker Mylan NV said on Tuesday it is recalling select batches of blood pressure medicine valsartan in the United States after they were found to contain trace amounts of a probable cancer-causing impurity. (Source: Reuters: Health)
Source: Reuters: Health - November 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
European authorities suspend Mylan's manufacturing license for hypertension drug
Mylan NV ’s manufacturing license for valsartan was suspended by European authorities after NDEA was found in some batches of the hypertension drug made at the company’s facility in Hyderabad, India, The European Medicals Agency said on Monday.
Suspension of Mylan’s (Nasdaq: MYL) certificate of compl iance with European standards for quality testing effectively prohibits the use of its valsartan in EU medicines, EMA’s release said.
NDEA in high doses is classified as a substance that could… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 20, 2018 Category: American Health Authors: Patty Tascarella Source Type: news
EU cracks down on blood pressure medicine made by Mylan
European Union authorities on Monday stepped in to effectively ban sales of blood pressure medicine valsartan made by an India-based unit of Mylan NV after some batches were found to contain a probable cancer-causing impurity, the latest in a global crackdown. (Source: Reuters: Health)
Source: Reuters: Health - November 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
European authorities crack down on blood pressure medicine made by Mylan
European Union authorities are cracking down on blood pressure medicine valsartan made by a unit of Mylan NV after an impurity was found in some batches of the treatment. (Source: Reuters: Health)
Source: Reuters: Health - November 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Blood Pressure Drug Recall Expands Again; Meds May Be Tainted With Cancer-Causing Chemical
(CNN) — The US Food and Drug Administration says another heart medicine is being voluntarily recalled after tests showed that it was tainted with a potential cancer-causing chemical.
The recall includes one lot of Sandoz’s losartan potassium hydrochlorothiazide 100 milligram/25 milligram tablets with the lot number JB8912. Patients use these drugs to keep their high blood pressure in check.
The drug is being recalled because the active ingredient has tested positive for N-Nitrosodiethylamine or NDEA, a suspected human and animal carcinogen that is used in gasoline as a stabilizer for industry materials and as a...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 12, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News Local TV Valsartan Source Type: news
PIONEER-HF: In-Hospital ARNI Shows Biomarker Benefit vs ACE-I PIONEER-HF: In-Hospital ARNI Shows Biomarker Benefit vs ACE-I
Prognostically powerful natriuretic peptides fell further in patients with stabilized, recently decompensated heart failure who were started in hospital on sacubitril/valsartan compared with enalapril.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 12, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
FDA Announces Recall Of Another Heart Medicine For Possible Cancer Risk
(CNN) — The US Food and Drug Administration is alerting patients of another recall of medicine used to treat high blood pressure, for a potential cancer risk due to contamination. This time, SciGen is recalling certain lots of irbesartan.
The recalled lot will have “Westminster Pharmaceuticals” and “GSMS Inc.” on the label, according to the FDA list.
Another heart medicine, valsartan, has also been recalled recently due to contamination.
Irbesartan is an angiotensin II receptor blocker, or ARB. This is a drug that blocks a potent chemical in the blood called anigiotensin, which causes muscles ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 1, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Local TV Recall Source Type: news
Treatment of hypertension for low-risk patients questioned
Study funds little evidence of benefits from treatment Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Avoid BP-lowering drugs in stroke Adding insulin to metformin linked to higher mortality Stroke rate higher in HIV patients Recurrent stroke more likely at very low BP (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 1, 2018 Category: UK Health Source Type: news
FDA: Irbesartan Under Recall Too in the Midst of Valsartan Saga
(MedPage Today) -- Another ARB found to contain a potential carcinogen in some lots (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 31, 2018 Category: American Health Source Type: news
